PCVX Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of 31.72%. Vaxcyte, Inc.'s return on equity of -20.68% beat Eli Lilly & Co.'s return on equity of 106.26%.

Vaxcyte, Inc. has a consensus price target of $102.11, signalling upside risk potential of 121.74%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,116.33 which suggests that it could grow by 4.96%. Given that Vaxcyte, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vaxcyte, Inc. is more attractive than Eli Lilly & Co..

Vaxcyte, Inc. has a beta of 1.339, which suggesting that the stock is 33.904% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Vaxcyte, Inc.'s net income of -$212.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 52.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 16.32x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of -19.69%. Vaxcyte, Inc.'s return on equity of -20.68% beat Moderna, Inc.'s return on equity of -30.18%.

Vaxcyte, Inc. has a consensus price target of $102.11, signalling upside risk potential of 121.74%. On the other hand Moderna, Inc. has an analysts' consensus of $36.60 which suggests that it could grow by 6.71%. Given that Vaxcyte, Inc. has higher upside potential than Moderna, Inc., analysts believe Vaxcyte, Inc. is more attractive than Moderna, Inc..

Vaxcyte, Inc. has a beta of 1.339, which suggesting that the stock is 33.904% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $1B. Vaxcyte, Inc.'s net income of -$212.8M is lower than Moderna, Inc.'s net income of -$200M. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 5.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of -287.29%. Vaxcyte, Inc.'s return on equity of -20.68% beat Novavax, Inc.'s return on equity of --.

Vaxcyte, Inc. has a consensus price target of $102.11, signalling upside risk potential of 121.74%. On the other hand Novavax, Inc. has an analysts' consensus of $12.78 which suggests that it could grow by 75.76%. Given that Vaxcyte, Inc. has higher upside potential than Novavax, Inc., analysts believe Vaxcyte, Inc. is more attractive than Novavax, Inc..

Vaxcyte, Inc. has a beta of 1.339, which suggesting that the stock is 33.904% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.738%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Vaxcyte, Inc.'s net income of -$212.8M is lower than Novavax, Inc.'s net income of -$202.4M. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 4.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 1.16x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of 21.32%. Vaxcyte, Inc.'s return on equity of -20.68% beat Pfizer Inc.'s return on equity of 10.84%.

Vaxcyte, Inc. has a consensus price target of $102.11, signalling upside risk potential of 121.74%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Vaxcyte, Inc. has higher upside potential than Pfizer Inc., analysts believe Vaxcyte, Inc. is more attractive than Pfizer Inc..

Vaxcyte, Inc. has a beta of 1.339, which suggesting that the stock is 33.904% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Vaxcyte, Inc.'s net income of -$212.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.